Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Duke of Cambridge visits the University of Oxford’s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.

Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please check our latest COVID-19 research news or visit the COVID-19 trial website.

Oxford researchers have developed a vaccine in order to begin protecting people against the coronavirus as soon as possible and clinical trials are now underway to establish whether the vaccine generates immunity in humans. In May, the University of Oxford agreed a global licensing agreement with AstraZeneca, the UK-based pharmaceutical company, for the commercialisation and manufacturing of this potential vaccine.

On 24 June the Duke paid a visit to the Oxford Vaccine Centre facility at the Churchill Hospital in Oxford where the vaccine has been developed and trials are now underway. During his visit, The Duke was briefed about the Group’s work by Professor Sarah Gilbert, Professor of Vaccinology at the Jenner Institute, who developed the vaccine and Professor Andrew Pollard, Professor of Paediatric Infection and Immunity at the University of Oxford, who is leading the clinical trial team.

'It was a huge honour to host His Royal Highness the Duke of Cambridge at the Oxford Vaccine Centre, at Oxford University, today and to describe our ongoing work to develop and trial an effective vaccine against the global threat that is coronavirus. We were delighted at the time he took to thank the members of the public who volunteered to take part in this important research. His words of praise to not only the staff he met but all those contributing to this important work has given our teams, who have been working very hard at unprecedented urgency for several months, a real boost, as we continue to tackle this current and pressing challenge,' said Professor Andrew Pollard, Professor of Paediatric Infection and Immunity at the University of Oxford and Chief Investigator of the Oxford Vaccine Trial.

His Royal Highness was shown around the manufacturing laboratory where the vaccine has been produced and was also given a tour of the laboratory where samples from the clinical trial are being examined by researchers. The trials began on 23 April, with ten thousand people across the UK in the process of being vaccinated in the latest study to assess the potential success of the treatment. This week, trials have begun in Brazil and South Africa. 

During his time at the facility, The Duke met individuals who are part of the trial and spoke to them about their experience of the process. He also heard from staff who have been coordinating the trial across nineteen sites in the UK.

The UK Government has provided £84 million for the University of Oxford to develop and manufacture its coronavirus vaccine. The University's partnership with AstraZeneca means the vaccine will be available globally on a non-profit basis during the pandemic period, including to low and middle income countries.

The Duke also spoke via video call to representatives from AstraZeneca and the University of Oxford as well as from CEPI (Coalition for Epidemic Preparedness Innovations) and Gavi, The Vaccine Alliance. He heard how the AstraZeneca-Oxford partnership has placed British science and innovation at the heart of the global response to the pandemic. 

An agreement between the University of Oxford, AstraZeneca and the UK Government means the UK will have immediate access to the vaccine, should it be successful. However, crucially it will also be made available in a broad and equitable way, including to low and middle income countries. The Duke heard how committed all partners are to ensure global, equitable access for all who need a vaccine as a crucial way to end the pandemic and support the global economic recovery.

Similar stories

It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard

A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees

Novel all-in-one vaccine developed to tackle future coronavirus threats

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

One billion doses: A moment to celebrate but not a time to be complacent

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Professor of Paediatric Infection and Immunity, takes a moment to reflect on one billion doses of the Oxford coronavirus vaccine released worldwide.